Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Spero Therapeutics
Biotech
GSK's bet on rejected UTI antibiotic pays off with phase 3 win
GSK’s decision to swoop in and save Spero Therapeutics’ antibiotic three years ago appears to have paid off based on a fresh phase 3 readout.
James Waldron
May 28, 2025 8:42am
Scholar Rock rocks the boat with new execs—Chutes & Ladders
May 2, 2025 8:30am
Spero halts development on another antibiotic
Mar 28, 2025 7:05am
Spero speared by antibiotic flop, triggering 39% workforce cut
Oct 30, 2024 6:30am
Biogen CMO Maha Radhakrishnan joins Sofinnova—Chutes & Ladders
Aug 9, 2024 8:30am
Fierce 15: Where are they now?
Jul 26, 2024 6:50am
